Kornimate/medical-research-clean huggingface dataset:
cardiosafe+: a platform for telerehabilitation and monitoring of patients with heart problems

Conditions: Cardiovascular Diseases

Summary: the use of telerehabilitation seems to be effective in managing complications after suffering a cardiovascular pathology. the use of the cardiosafe+ digital platform is suggested for the management of these complications. for this reason, an intervention will be carried out to determine the effectiveness of this platform. a total of 60 participants will be recruited to carry out a home-exercise intervention through cardiosafe+ for 6 weeks. maximun respiratory pressures, exertion capacity, and subjective sensation of exertion will be assessed.

this intervention seeks to determine the effectiveness of the cardiosafe+ digital platform in aiding individuals recovering from cardiovascular pathologies. by involving a group of 60 participants in a structured six-week home-exercise program using the cardiosafe+ platform, the objective is to measure and evaluate various factors related to their physical well-being and recovery. key components to be evaluated include: maximal respiratory pressures: this involves measuring the maximum force generated during inspiration and expiration, which can indicate respiratory muscle strength and function. exertion capacity: the assessment aims to gauge the participants' ability to engage in physical activities, potentially reflecting improvements in overall cardiovascular fitness and endurance. subjective sensation of exertion: this component involves understanding how the participants perceive and rate their own exertion during exercises, contributing to insights about their subjective experience and effort perception. the intervention's objective is to collect data on these parameters before and after the six-week exercise program utilizing the cardiosafe+ digital platform. this data will help determine the effectiveness of the platform in aiding individuals recovering from cardiovascular pathologies and could provide valuable insights for further implementing tele-rehabilitation in managing such health complications.

Eligibility criteria:
inclusion criteria: * people who present a cardiovascular pathology with more than one year of evolution. * to be in a stable medical situation. * to have access to technological resources and knowledge for their use. exclusion criteria: * people who present any contraindication established for carrying out physical activity. * people who present insufficient capacity to understand and obey the instructions offered by the researchers, both in the evaluation and in the intervention. * people who have a cardiac pathology with obvious fluctuations in the course of the disease. * the presence of an acute episode of the disease during the intervention period.
histocompatibility leukocyte antigen (hla)-a*2402 restricted peptide vaccine therapy in patients with non-small cell lung cancer

Conditions: Non Small Cell Lung Cancer

Summary: the purpose of this study is to evaluate the safety and time to progression of hla-a\*2402 restricted epitope peptides urlc10, ttk and koc1 emulsified with montanide isa 51.

urlc10,ttk and koc1 has been identified as cancer specific molecules especially in non small cell lung cancer using genome-wide expression profile analysis by cdna microarray technique. we have determined the hla-a\*2402 restricted epitope peptides derived from these molecules and identified that these peptides significantly induce the effective tumor specific ctl response in vitro and vivo. according to these findings, in this trial, we evaluate the safety, immunological and clinical response of those peptides. patients will be vaccinated twice a week for 8 weeks. on each vaccination day, the urlc10-177 peptide(1mg), ttk-567 peptide(1mg) and koc1-508 peptide(1mg) mixed with montanide isa 51 will be administered by subcutaneous injection. repeated cycles of vaccine will be administered until patients develop progressive disease or unacceptable toxicity, whichever occurs first. in the phase i study, we evaluate the safety and tolerability of these peptide vaccine. in the following phase ii study, we evaluate the immunological and clinical response of this vaccine therapy.

Eligibility criteria:
inclusion criteria: disease characteristics * advanced or recurrent non small cell lung cancer * second line or later therapeutic status patient characteristics * ecog performance status 0-2 * life expectancy \> 3 months * hla-a\*2402 * laboratory values as follows * 2000/mm3\<wbc\<15000/mm3 * platelet count\>100000/mm3 * bilirubin \< 3.0mg/dl * asparate transaminase \< 150iu/l * alanine transaminase \< 150iu/l * creatinine \< 3.0mg/dl * able and willing to give valid written informed consent exclusion criteria: * pregnancy(woman of childbearing potential:refusal or inability to use effective means of contraception) * breastfeeding * active or uncontrolled infection * concurrent treatment with steroids or immunosuppressing agent * prior chemotherapy,radiation therapy, or immunotherapy within 4 weeks * uncontrolled brain and/or intraspinal metastasis * decision of unsuitableness by principal investigator or physician-in-charge

Keywords: hla-a*2402 peptide vaccine urlc10 ttk koc1
cardiovascular complications of carfilzomib

Conditions: Myeloma; Heart Failure; Hypertension

Summary: cardiovascular toxicity of carfilzomib, a last generation proteasome inhibitor, is highly incident according to retrospective data. prospective cohort study of patients initiated on carfilzomib.


Eligibility criteria:
inclusion criteria: * intention to treat by carfilzomib exclusion criteria: * history of carfilzomib treatment

Keywords: adverse drug event
soft and hard tissues evaluation around immediately placed new implant design

Conditions: Peri-implant Mucositis; Dental Implant Failed

Summary: patients were randomly divided into maxi-z plus dental implant group versus maxi-z implant group

after tooth extraction implants will be placed immediately and provisional restoration will be placed in both groups to detect the advantaged and drawbacks of newly designed maxi-z plus dental implant versus maxi-z dental implant

Eligibility criteria:
inclusion criteria: * good health * unrestorable, periodontal healthy teeth exclusion criteria: * systemic disease * periodontal disease * presence of abscess

Keywords: platform switched implants platform matched implants
detection of cancer-specific active proteases in blood via fluorescence

Conditions: Pancreatic Cancer

Summary: the primary objective is to develop a rapid in vitro screening assay for detection of pancreatic cancer biomarkers in blood of patients with pancreatic cancer.

the goal of the project is to develop a rapid in vitro screening assay for detection of cancer biomarkers in blood. the aim is testing and optimization of nanoparticle sensors, based on cyanine dyes that are chemically linked to fe/fe3o4 nanoparticles via protease-selective consensus (cleavage) sequences. the focus is on the quantitative determination of active cancer-specific proteases in blood via simple fluorescence measurements. the matrix metalloproteinases, urokinase-type plasminogen activator, and cathepsins, are up-regulated in the vast majority of progressing cancers and can, therefore, serve as markers for cell survival/tumor progression, angiogenesis, and tissue remodeling/invasion

Eligibility criteria:
inclusion criteria: inclusion criteria for pancreatic cancer patients: * patients will either have a histologic diagnosis of pancreatic carcinoma or a clinical picture consistent with pancreatic cancer and will be undergoing surgery or a diagnostic procedure to confirm the diagnosis. * patients will have had no prior treatment or surgery inclusion criteria for healthy subjects: * subjects will have no prior history of any cancer exclusion criteria: exclusion criteria for pancreatic cancer patients * any prior treatment for pancreatic cancer * poorly controlled diabetes exclusion criteria for healthy subjects * poorly controlled diabetes

Keywords: pancreatic cancer nanoparticle proteases cell survival tumor progression angiogenesis tissue remodeling/invasion
dental implant stability when using the densah bur™ bone compaction process to prepare dental implant sites

Conditions: Missing Teeth

Summary: the primary objective of this study is to determine if the use of a bone compaction process (osseodensification) (densah™ bur: versah osseodensification company™) to prepare dental implant sites, in human subjects, results in increased bone-ridge width, increased compact bone in the outer wall of the prepared sites, and dental implant stability.

the proposed project will be an observational, case-series study. the investigators anticipate enrolling 40 study subjects. treatment procedures: following initial treatment planning discussions between the dentists and their patients regarding all of their dental treatment options, those patients who opt to have dental implants placed will be approached to discuss participation in the current study. before entry into the study, the investigator or an authorized member of the investigational staff will explain to potential subjects the aims, methods, reasonable anticipated benefits, and potential hazards of the study, and any discomfort it may entail. subjects will be informed that their participation is voluntary and that they may withdraw consent to participate at any time. they will be informed that choosing not to participate will not affect the care the subject will receive for the treatment of their condition. subjects will be told that alternative treatments are available and that if they decline to take part in the present study that such a refusal will not prejudice future treatment. those patients who are willing to participate will be scheduled for their initial and follow-up dental implant visits at the school of dentistry. at the baseline visit the study outcome data will be collected; including: 1) measuring the bone-ridge width, before and after implant site preparation (drilling); 2) intraoral photographs of the prepared opening; 3) dental implant torque readings will be obtained; and 4) isq as measure of both initial and the dynamic development of osseointegration (the formation of a direct interface between the dental implant and bone) over time. the isq measurements will be collected again at three and six-weeks post treatment.

Eligibility criteria:
inclusion criteria: 1. males and females 2. ages 18-80 years of age 3. missing at least one tooth. 4. capable of giving informed consent exclusion criteria: 1. patient is a pregnant female 2. patient smoking more than 5 cigarettes per day 3. patient has a history of alcoholism or drug abuse during the last 5 years 4. patient with uncontrolled hypertension or diabetes 5. patient has a malignant tumor 6. patient is on daily dose of steroids 7. patient with history of chemotherapy or radiation for the last 12 months 8. patient who is immuno suppressed 9. patient with titanium allergy 10. subject should not be a homeless person
a study to find the minimum inhibitory concentration of kae609 in adult male patients with p. falciparum monoinfection

Conditions: Malaria

Summary: this study aims to determine the minimum inhibitory concentration of kae609 in adult male patients with acute, uncomplicated malaria due to p.falciparum monoinfection after single dosing with kae609

there will be a total of approximately 45 patients recruited into this study and six doses of kae609 and will be investigated.the dose groups will run in sequence. patient will be given a single dose of kae609 and be followed up for 42 days.

Eligibility criteria:
key inclusion criteria: * monoinfection with p. falciparum confirmed by microscopy * asexual p. falciparum parasitemia count of 5,000 to 50,000/µl * axillary temperature ≥37.5 ºc or oral/tympanic/rectal temperature ≥38 ºc; or similar documented temperature during the previous 24 hours * body weight between 40 to 90 kg key exclusion criteria: * signs and symptoms of severe malaria according to world health organization (who) 2010 criteria * mixed plasmodium infection, i.e. infection with more than one species of malaria parasites * use of other investigational drugs within 30 days or within 5 half-lives of enrollment, whichever is longer * history of antimalarial use within 2 months of screening * use of any antibiotics with antimalarial activity or other prohibited medication within 14 days of screening * long qt syndrome or qtc using fridericia's formula \>430 msec * history of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases * hemoglobin level \<10 g/dl * liver disease or injury as indicated by elevated liver tests such as sgpt (alt) or sgot (ast) \>2 times the upper limit of normal * renal dysfunction as indicated by serum creatinine \>2 times the upper limit of normal in the absence of dehydration; in case of dehydration, serum creatinine should be \<2 times the upper limit of normal after oral or parental rehydration * known to be immunocompromised (including hiv infection) or are receiving immunosuppressive therapy at the time or enrollment; hiv testing is not required * known history of hepatitis b or c; testing is not required * febrile condition due to diseases other than malaria (e.g. acute lower respiratory tract infection), known underlying chronic or severe disease (e.g. cardiac, hepatic, renal, gastrointestinal, neurologic, or psychiatric disease), or any condition precluding enrollment into this study according to the investigator * severe vomiting defined as \>3 times during the previous 24 hours or inability to tolerate oral medication; severe diarrhea defined as ≥3 watery stools during the previous 24 hours * severe malnutrition defined by a body mass index (bmi) \<18.5 kg/m2 or unintentional loss of weight ≥10% with evidence of suboptimal intake resulting in loss of subcutaneous fat and/or severe muscle wasting * active tuberculosis or history of taking anti-tuberculosis medications within 24 months prior to screening

Keywords: malaria, kae609
a study of ly2157299 in participants with advanced hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma

Summary: the main purpose of this study is to evaluate the safety and effectiveness of the study drug known as ly2157299 in participants with hepatocellular carcinoma.


Eligibility criteria:
inclusion criteria: * have histological evidence of a diagnosis of hcc not amenable to curative surgery. * have child-pugh class a. * have the presence of measurable disease. * have adequate organ function. * have a performance status of ≤1 on the eastern cooperative oncology group (ecog) scale. * if male or female with reproductive potential, must agree to use medically approved contraceptive precautions during the trial and for 3 months following the last dose of study drug. * if females with childbearing potential, must have had a negative serum pregnancy test 7 days prior to the first dose of study drug. * are able to swallow capsules or tablets. * have available diagnostic or biopsy tumor tissue. exclusion criteria: * have received previous systemic treatment for advanced disease. * have known hcc with fibro-lamellar or mixed histology. * have presence of clinically relevant ascites. * have had a liver transplant. * have moderate or severe cardiac disease. * have active or uncontrolled clinically serious hepatitis b virus or hepatitis c virus infection. * have experienced grade 3 or 4 gastrointestinal bleeding or any variceal bleeding episode in the 3 months prior to enrollment requiring transfusion or endoscopic or operative intervention. * have esophageal or gastric varices that require immediate intervention or represent a high bleeding risk. * had major surgery within 4 weeks prior to the study randomization.

Keywords: transforming growth factor beta (tgf-β)
a comparison of activities of daily living, physical fitness and quality of life in obese and healthy adolescents

Conditions: Obesity, Childhood; Healthy

Summary: it is known that activities of daily living, physical fitness, exercise capacity and quality of life are affected by the obesity. it is aimed to determine the effects obesity on daily living activities, physical fitness, exercise capacity and quality of life in obese adolescents compared to healthy subjects in this study. the relationship between these parameters and the activities of daily living which are less studied in obese adolescents will be evaluated.

obesity among children, adolescents and adults has emerged as one of the most serious public health problems in the 21st century. there has been a significant decrease in the exercise capacity, physical fitness and activities of daily living of children and adolescents with the increase in the prevalence of obesity over the last decade. obesity can cause not only health problems but also psychological effects. this situation have negative effects on the quality of life. the effect of these parameters on healthy individuals and obese adolescents will be demonstrated by this study and will guide the rehabilitation of obese adolescents.

Eligibility criteria:
inclusion criteria: healthy group: * being normal weight according to bmi reference system, * being between the ages of 10-18 and volunteer to participate in the research, * being able to walk and cooperate obese group: * obesity diagnosis according to bmi reference system, * being between the ages of 10-18 and volunteer to participate in the research, * being able to walk and cooperate. exclusion criteria: healthy group: * comorbidities that may affect exercise performance and other physical tests, * having cardiovascular problems, musculoskeletal and neurological disease, * having cognitive or motor limitation or other chronic diseases. obese group: * having a neurological disease or other clinical diagnosis that may affect cognitive status, * having musculoskeletal and neurological diseases, symptomatic heart disease, lung disease, diabetes, hypertension and malignant disease that may affect exercise performance, * using medication that affects appetite and weight.

Keywords: physical fitness exercise capacity activities of daily living quality of life
cd19/cd22-targeted chimeric antigen receptor engineered t cell (cart) in b-cell acute lymphoblastic leukemia.

Conditions: Leukemia, B-cell

Summary: this is a single center, open-label ,phase 1/2 study to evaluate the safety and efficacy of targeted cd19/cd22 chimeric antigen receptor engineered t cell immunotherapy (cart) in the treatment of cd19/cd22 positive relapsed or refractory b-cell acute lymphoblastic leukemia.

the patients will receive infusion of cart cells targeting cd19 and cd22 to confirm the safety and efficacy of cd19/cd22 cart cells in relapsed or refractory b-cell acute lymphoblastic leukemia.

Eligibility criteria:
inclusion criteria: * male or female patients with cd19+/cd22+ relapsed/refractory b-cell acute lymphoblastic leukemia who have a dismal prognosis (estimated survival from several months to \<2 year). the study will enroll 20 evaluable patients as follows: * age 6-65 years. * left ventricular ejection fractions≥ 0.5 by echocardiography. * creatinine \< 1.6 mg/dl. * aspartate aminotransferase/aspartate aminotransferase \< 3x upper limit of normal. * bilirubin \<2.0 mg/dl. * karnofsky performance status ≥ 60 * expected survival time ≥ 3 months (according to investigator's judgement) exclusion criteria: * pregnant or lactating women. * uncontrolled active infection. * active hepatitis b or hepatitis c infection. * class iii/iv cardiovascular disability according to the new york heart association classification. * hiv infection. * patients with history of seizure * active central nervous system leukemia

Keywords: cd19 cd22
mechanical ventilation with neurally-adjusted ventilatory assist in patients with ards

Conditions: Acute Respiratory Distress Syndrome

Summary: neurally-adjusted ventilatory assist (nava) is a ventilatory mode that uses the electrical activity of the diaphragm to control the mechanical ventilator, offering inspiratory assistance in proportion to respiratory effort to patients who need artificial ventilatory support. it has been shown to improve the interaction between the patient and the mechanical ventilator in several clinical situations, but no previous studies have tried to use it for patients with a severe type of respiratory insufficiency, called acute respiratory distress syndrome (ards). patients with ards benefit from a mechanical ventilatory strategy that includes low inspiratory volumes (tidal volumes) and limited airway pressures, but the application of such strategy frequently requires high levels of sedation. the investigators' hypothesis is that nava can be used for patients with ards, and that it will not be associated with excessive tidal volumes or elevated airway pressures.

neurally adjusted ventilatory-assist(nava) is an assisted ventilatory mode that captures the electrical activity of the diaphragm and uses it to initiate and terminate the inspiratory phase, offering inspiratory assistance in proportion to patient effort, cycle by cycle. studies in animals and humans have shown that nava reduces the work of breathing and improves patient-ventilator interaction in comparison with traditional modes. because it is an assisted mode, its use requires less sedation. the use of nava could contribute to the reduction of complications of prolonged mechanical ventilation in patients with acute respiratory distress syndrome (ards) submitted to protective ventilation with low tidal volumes and limited plateau pressure. however, there are no studies with nava in the acute phase of ards, in which assisted-controlled modes are generally used, allowing for adjustment of tidal volume and/or plateau pressure. with this project, the investigators intend to evaluate the behavior of nava mode in the acute phase of mechanical ventilation in ards patients, to assess whether this mode can be used to deliver an assisted lung protective ventilation strategy.

Eligibility criteria:
inclusion criteria: * mechanical ventilation for more than 24 hours; * diagnosis of ards * clinical indication of lung protective mechanical ventilation by the icu team; * presence of active inspiratory efforts for more than 6 hours exclusion criteria: * patients under 18 years; * pregnant women; * trauma or burns of the face that hinder the passage of gastro-esophageal catheter; * nasal pathologies that prevent the progression of gastro-esophageal catheter; * ulcers of the esophagus or stomach; * documented esophageal varices; * tracheostomized patients; * instability of the chest wall or diaphragmatic injury; * hemodynamic instability, defined as the need to increase vasoactive drugs in the last two hours in order to maintain the mean arterial pressure above 60 mmhg).

Keywords: ards